|
gptkbp:instanceOf
|
gptkb:chemical_compound
World Health Organization essential medicine
antimycobacterial drug
|
|
gptkbp:ATCCode
|
J04BA01
|
|
gptkbp:brand
|
Lamprene
|
|
gptkbp:CASNumber
|
2030-63-9
|
|
gptkbp:category
|
phenazine
antimycobacterial agent
antileprotic agent
chlorinated compound
|
|
gptkbp:chemicalFormula
|
C27H22Cl2N4
|
|
gptkbp:color
|
red
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:discoveredBy
|
G. Y. Chen
|
|
gptkbp:discoveredIn
|
1954
|
|
gptkbp:eliminationHalfLife
|
70 days
|
|
gptkbp:excretion
|
fecal
biliary
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
clofazimine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to bacterial DNA
inhibits mycobacterial growth
|
|
gptkbp:meltingPoint
|
210–212 °C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
473.41 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
2794
DB00845
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dry skin
gastrointestinal disturbances
skin discoloration
phototoxicity
|
|
gptkbp:solubility
|
practically insoluble in water
|
|
gptkbp:UNII
|
1EUV8Q1D2L
|
|
gptkbp:usedFor
|
gptkb:Mycobacterium_avium_complex
leprosy
multidrug-resistant tuberculosis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:dapsone
gptkb:Mycobacterium_leprae
|
|
gptkbp:bfsLayer
|
7
|